A.R.T. Advisors’s Carisma Therapeutics CARM Stock Holding History

A.R.T. Advisors’s Portfolio CARM Stock Details CARM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-755	Closed	-$11K	–	100
2020 Q2	$11K	Buy	+755	New	+$10.2K	0.02%	270
2020 Q1	–	Sell	-2,795	Closed	-$58K	–	196
2019 Q4	$58K	Buy	+2,795	New	+$64.2K	﹤0.01%	1245
2019 Q2	–	Sell	-3,318	Closed	-$68K	–	1365
2019 Q1	$68K	Buy	+3,318	New	+$57.3K	﹤0.01%	1202
2017 Q3	–	Sell	-2,482	Closed	-$77K	–	1369
2017 Q2	$77K	Buy	+2,482	New	+$82.8K	﹤0.01%	1276
2016 Q4	–	Sell	-665	Closed	-$37K	–	1288
2016 Q3	$37K	Buy	+665	New	+$49.5K	0.01%	604

Other funds holding CARM

TRV GP Boston, Massachusetts $18.9M AUM 541.67% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

KCM

Kingdon Capital Management New York $976M AUM 66.76% 1-Year Est. Return

Eversept Partners New York $1.93B AUM 160.8% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $5.69B AUM 60.64% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return

A.R.T. Advisors's CARM Position: Q3 2020 in Review

A.R.T. Advisors sold out of Carisma Therapeutics (CARM) in Q3 2020, closing a stake of 755 shares — an estimated $11K sold.

A.R.T. Advisors first reported a position in CARM in Q3 2016 and held it in 5 quarters. The position peaked at $77K in Q2 2017. 45 funds tracked by Wall St. Rank hold CARM as of Q3 2020.

A.R.T. Advisors reported no remaining Carisma Therapeutics position as of Q3 2020 after selling out during the quarter.
A.R.T. Advisors sold 755 Carisma Therapeutics shares in Q3 2020, an estimated $11K.
A.R.T. Advisors first reported a position in Carisma Therapeutics in Q3 2016 and held it in 5 quarters.
A.R.T. Advisors's Carisma Therapeutics position peaked at $77K in Q2 2017.
45 funds tracked by Wall St. Rank held Carisma Therapeutics as of Q3 2020.

Based on A.R.T. Advisors's 13F filing for Q3 2020, filed 16 Nov 2020.